Monday, February 23, 2026

Post-Market Sees Mixed Signals After Day's Decline

U.S. equities concluded Monday's trading session in the red, with the S&P 500 SPY $682.39 ▼ 0.79% declining amidst persistent global tariff anxieties and a significant pharmaceutical sector setback from NVO. As the market entered post-hours, a collection of corporate earnings and strategic developments offered a mixed outlook heading into Tuesday.

The artificial intelligence narrative continues to build momentum in after-hours. Z announced a partnership with GOOGL $311.49 ▼ 2.38% to enhance home-buying guidance through AI, a positive for both companies. Further bolstering the AI infrastructure theme, NBIS acquired agentic search software provider Tavily, expanding its cloud infrastructure with backing from major tech firms like META $637.35 ▼ 2.33% and MSFT $384.64 ▼ 2.63%. AAPL $266.40 ▲ 1.08% also made headlines with reports of shifting some Mac Mini production to Houston, a move that could be seen as positive for domestic manufacturing.

However, a significant negative surfaced in the aerospace sector. News broke of a former DJ sentenced to prison for a $54 million fake plane parts scheme, impacting major manufacturers like BA $230.48 ▼ 0.61% and EADSY, and airlines such as DAL, AAL, and RYAAY, raising safety concerns across the industry.

In other corporate news, TOP TOPS secured nine new tankers with long-term charters, a bullish sign for the shipping company. Meanwhile, BTC extended its recent decline, falling over 5% to below $64,000, reflecting continued 'Risk-Off' sentiment in the crypto market. While China's stocks reopened higher on hopes for tariff relief, this offered a nuanced counterpoint to the broader global trade fears that weighed on U.S. markets throughout Monday.

Stocks Closed Lower; Post-Market Earnings & AI Offer Mixed Signals

U.S. equities concluded Monday's trading session in the red, with the S&P 500 SPY $682.39 ▼ 0.79% declining amidst persistent global tariff anxieties and a significant pharmaceutical sector setback from NVO. As the market entered post-hours, a collection of corporate earnings and strategic developments offered a mixed outlook heading into Tuesday.

On the positive side, several companies reported strong financial performances. CALX highlighted robust H1 FY26 growth driven by strategic wins, while WDS shares climbed to an 18-month high following solid FY results and a dividend announcement. CHT also saw its stock jump significantly after strong Q1 2026 performance and a 91% profit surge for 1H26. Further positive results came from CWP reporting robust Q1 2026 growth, DBI showing resilient Q4 2025 earnings, and AUB AUB delivering resilient Q1 2026 results. In legal news, UPS UPS secured a crucial victory, clearing the way for its Driver Choice Program amid planned job cuts, which could streamline its workforce.

The artificial intelligence narrative continued to evolve, with NVDA $191.59 ▲ 0.09% remaining a focal point. Reports emerged that China’s DeepSeek AI trained its model on NVDA's top chips, even amidst existing US restrictions, underscoring the chipmaker's pervasive demand and technological lead.

Conversely, some firms faced headwinds. Hims & HIMS saw investor worries mount over profits due to its expansion plans and Super Bowl ad. MAD experienced a stock drop despite reporting 18% revenue growth in 1H FY26, suggesting underlying margin pressures, a sentiment echoed by NAN which reported H1 FY26 revenue growth but also faced margin concerns.

In macro developments, China's central bank held benchmark lending rates unchanged for the ninth consecutive month, aiming to balance economic support with currency stability. Reports also indicated the U.S. had explored joint intervention with Japan on Yen rates. Broader Asian stocks wobbled, reflecting the previous day's selloff on Wall Street and ongoing global uncertainty.

Post-Market Sees Mixed Bag After Day's Tariff, Pharma Drag

U.S. equities closed lower on Monday, with broad market pressure from lingering global tariff uncertainty and a significant pharmaceutical setback. As the market moved into after-hours, a mixed bag of corporate news emerged, with legal action, leadership updates, and active investment plays taking center stage.

Amidst the day's tariff-driven volatility, FedFDX made headlines by suing the U.S. government, seeking a full refund for Trump-era emergency tariffs. This legal challenge directly follows a recent Supreme Court ruling and could have significant implications for companies impacted by previous trade policies.

In the financial sector, JPJPM $297.76 ▼ 3.49% saw news that its long-standing CEO, Jamie Dimon, plans to remain at the helm for several more years, providing continuity for the banking giant. Meanwhile, Cathie Wood's ARK Invest was busy, reportedly increasing its stake in CRWV with a $3.46 million bet ahead of its critical earnings report later this week. This move by ARK also included additional buys in AI-related names like NVDA $191.59 ▲ 0.09% and **AMD**, while shedding positions in DKNG, PD, and PINS. The focus on **CRWV** is particularly notable given its deep ties to **NVDA** and recent concerns around its financing for ambitious data center projects. Its upcoming earnings report is expected to provide crucial clarity on power, capacity, and financing conditions amidst the relentless AI spending boom.

Several companies reported positive financial results after hours. U.S. USGO presented slides showing a shareholder yield topping 9% amid a gold rally. VIR beat Q4 2025 earnings expectations, and Noumi Ltd (NOU.AX) reported record growth for H1 FY26. PGG Wrightson (PGW.NZ) also saw strong H1 FY2026 growth in revenue and EBITDA. Conversely, Singapore's UOB (UOVEY) missed Q4 profit estimates due to weaker trading income, adding to the day's scattered corporate performance.

Market Retreats on Tariffs, Pharma; AI Investments Highlight Post-Market

U.S. equities closed lower on Monday, with the DJIA down 1.66%, as global tariff uncertainty and a significant pharmaceutical setback weighed on investor sentiment. The broader market experienced a "Risk-Off" day, with the S&P 500 SPY $682.39 ▼ 0.79% also ending in negative territory, driven by lingering protectionist rhetoric and a major trial failure from NVO.

Post-market hours saw a mixed bag of corporate news, with several companies moving on earnings and strategic developments. BWXT BWXT jumped on strong Q4 results and a raised 2026 outlook. Conversely, WHR tumbled after announcing equity offering plans. Electric vehicle giant TSLA $399.58 ▼ 1.91% faced skepticism over a new affordable Cybertruck trim, adding to the day's pressure from tariff-related concerns that also impacted names like AAPL $266.40 ▲ 1.08% and NVDA $191.59 ▲ 0.09%.

In other notable post-market action, BKNG $3869.83 ▼ 4.45% received an upgrade from Morgan Stanley on its AI outlook, and UBER $70.37 ▼ 16.35% expanded its services by acquiring parking app SpotHero. C $110.76 ▼ 3.98% announced a deal to sell a 24% equity stake in Banamex. The streaming wars continue, with PARA reportedly submitting a higher offer for WBD, intensifying competitive pressure for rivals like NFLX $76.05 ▼ 2.25%. DHT reported mixed Q4 earnings, while Brazil's GGB posted a slight increase in adjusted net profit.

The artificial intelligence narrative remained a dominant theme. While earlier in the day, software stocks, including those impacted by AI disruption fears like IBM $242.02 ▼ 22.49%, shed over $200 billion in market cap, analyst sentiment on tech giants like AMZN $205.30 ▼ 1.31%, GOOGL $311.49 ▼ 2.38%, and MSFT $384.64 ▼ 2.63% remained positive for their long-term AI potential. J.P. Morgan provided a nuanced take on the record surge in Gold prices, acknowledging short-term risks but reaffirming its role as a strategic diversifier for portfolios.

AI Investment Surge Counters Day's Tariff, Pharma Drag

U.S. equities closed lower on Monday, driven by lingering global tariff uncertainty and significant sector-specific headwinds, particularly a major pharmaceutical setback. However, a flurry of post-market corporate announcements, especially in the artificial intelligence sector, offered some bullish counterpoints, hinting at continued underlying growth narratives.

The market's downturn largely stemmed from renewed fears over protectionist trade policies, which rattled sentiment throughout the day. Compounding this, the pharmaceutical sector saw substantial volatility, most notably with shares of NVO plunging after its next-generation weight loss drug reportedly failed to match the efficacy of a rival product from LLY $1060.87 ▲ 1.18%. Meanwhile, IBM $242.02 ▼ 22.49% also tumbled over 10% during regular trading, sparked by fears of AI disruption to legacy systems after Anthropic launched a COBOL AI tool.

In contrast, the AI investment narrative continues to build momentum. After the bell, AMZN $205.10 ▼ 1.41% announced a massive $12 billion investment to build new AI data centers in Louisiana, part of its broader $200 billion AI capital expenditure plan for the year. This move aligns with bullish analyst views, as Gibbens Capital Management's CIO reiterated strong long-term confidence in tech giants like AMZN $205.10 ▼ 1.41%, GOOGL $310.61 ▼ 2.65%, and MSFT $383.94 ▼ 2.81%, viewing recent tech declines as buying opportunities and expecting strong earnings from NVDA $191.27 ▼ 0.07% later this week. Wells Fargo further underscored this trend, projecting hyperscaler compute capacity to double over the next two years.

Other post-market corporate highlights included Domino's DPZ, which posted better-than-expected earnings and gained ground by attracting lower-income diners with value offerings. WMT $125.75 ▲ 1.71% also garnered analyst upgrades and raised price targets on its digital growth strength. Financials like JPJPM $296.66 ▼ 3.85% and PNC were cited as strong plays, linked to a positive economic outlook. Beaten-down tech stocks like SHOP and MRVL were highlighted for their long-term potential in AI and e-commerce. On the downside, WBA widened job cuts amid store closures, TRUP hit a 52-week low, and multiple executives at MKS Inc. MKS sold significant stock. Bitcoin continued its recent tumble, with spot BTC ETFs, including IBIT, reportedly hemorrhaging billions in investor outflows.

Tariff Fears & Pharma Woes Drag Market; AI Sentiment Mixed

U.S. equities remain firmly in negative territory this afternoon, with the S&P 500 SPY $681.15 ▼ 0.97% down over 1.2% as a confluence of renewed global tariff threats and significant pharmaceutical sector setbacks weigh heavily on investor sentiment. Despite earlier clarity on some past trade duties, reports of fresh protectionist rhetoric have spurred a broad-based market retreat, signaling a distinct 'Risk-Off' mood.

The pharmaceutical sector is a key source of the downturn, with NVO shares plunging to near a five-year low after its next-generation weight loss drug reportedly failed to match the efficacy of a rival product in a critical trial, implying strength for LLY $1054.86 ▲ 0.61%. Adding to company-specific pressure, RHI hit a new 52-week low. Meanwhile, IBM tumbled more than 10% after Anthropic launched a COBOL AI tool, sparking fears of AI disruption within legacy systems, and MS $163.58 ▼ 5.97% also dipped on concerns about how AI agents could undermine borrowers.

The artificial intelligence narrative itself presents a mixed picture. While a new financial research report garnered attention for postulating a scenario of double-digit unemployment and a stock market crash if AI 'works,' contributing to a sell-off in software and tech names like NVDA $190.62 ▼ 0.41% and PLTR, some analysts remain bullish. Gibbens Capital Management's CIO, for instance, views current tech declines as buying opportunities and expects NVDA's upcoming earnings to be strong, also highlighting GOOGL $310.77 ▼ 2.60%, AMZN $204.40 ▼ 1.74%, and MSFT $383.97 ▼ 2.80% as long-term AI winners. Wells Fargo further supports the tech infrastructure build-out, projecting hyperscaler compute capacity to double over the next two years.

Amidst the broad market retreat, safe-haven asset GLD is tracking toward its longest winning streak in history, trading near all-time highs. In other news, WMT $126.10 ▲ 2.00% gained as analysts raised price targets on its digital growth strength, and a dip in the U.S. 30-year mortgage rate below 6% for the first time since 2022 offers a glimmer of hope for housing-related sectors like the SPDR S&P Homebuilders ETF XHB and iShares U.S. Home Construction ETF ITB. Conversely, NKE faces headwinds, reporting declining revenue as it loses market share to rivals. MKS Inc. MKS saw multiple EVP stock sales, often a bearish signal.

Market Sinks on Tariff Fears, Pharma, Cybersecurity Woes

U.S. equities are firmly in the red this Monday afternoon, with the S&P 500 SPY $682.01 ▼ 0.84% down over 1% as lingering concerns over global tariffs and a significant pharmaceutical setback continue to weigh on investor sentiment. Renewed protectionist rhetoric and escalating geopolitical tensions are creating a cautious backdrop for markets.

The pharmaceutical sector remains a key source of volatility. NVO is plunging further, hitting nearly a five-year low after its next-generation weight loss drug reportedly failed to match the efficacy of a rival product, implying strength for LLY $1062.70 ▲ 1.35%. Conversely, MRK $123.53 ▲ 0.99% is bucking the trend, hitting a new 52-week high.

Adding to the pressure, cybersecurity stocks are taking a hit for a second day, driven by fears of AI disruption as new tools like Anthropic's fuel concerns about evolving business models. Amidst the broad market retreat, safe-haven asset Gold is on track for its longest winning streak in history, trading near all-time highs.

The artificial intelligence narrative continues to evolve with mixed signals. NVDA $190.92 ▼ 0.26% remains a bright spot, with analysts expecting strong Q4 results, and the company is making a significant move back into the PC market with AI-focused laptop chips, partnering with DELL and leveraging ARM ARM and INTC $43.52 ▼ 1.58% architectures. However, broader caution persists, with some legendary investors warning on AI spending. Meanwhile, AAPL $268.07 ▲ 1.72% is showing resilience, with analysts noting reaccelerating App Store revenue growth and a strong installed base topping 2.5 billion devices. In corporate news, WBA continues to widen job cuts amid ongoing store closures as it reshapes its footprint under new ownership.

Market Retreats on Tariff Jitters, Pharma Plunge; Gold Shines

U.S. equities are firmly in the red this Monday afternoon, with the S&P 500 SPY $682.04 ▼ 0.03% down over 1% as lingering concerns over global tariffs and a significant pharmaceutical setback weigh on investor sentiment. Despite earlier clarity on some past trade duties, reports of fresh protectionist rhetoric, including a 'Trump tariff shock' impacting TSLA $398.63 ▼ 1.82% shares, have spooked markets. Geopolitical tensions also persist, with the U.S. ordering embassy personnel evacuation in Beirut.

The pharmaceutical sector remains a focal point for volatility. NVO is plunging further, extending its pre-market losses to hit a nearly five-year low after its next-generation weight loss drug reportedly failed to match a rival product in a key trial. Conversely, MRK $121.92 ▼ 0.04% is bucking the trend, hitting a new 52-week high. Meanwhile, Johnson & JNJ $242.81 ▼ 1.62% faces a lawsuit from Bayer, contributing to broader sector uncertainty.

The artificial intelligence narrative continues to evolve with a mix of bullish expansion and cautionary notes. NVDA $191.02 ▲ 2.41% is a major bright spot, with analysts expecting strong Q4 results and the company making a significant move back into the PC market with AI-focused laptop chips, partnering with DELL and leveraging ARM ARM and INTC $43.72 ▼ 0.33% architectures. SK HXSCL chairman pledged to expand high-bandwidth memory (HBM) production, calling it a 'monster chip' for AI. UBER $74.30 ▼ 11.67% is pushing deeper into autonomous solutions. AMZN $204.48 ▼ 0.13%-backed Anthropic is expanding its AI footprint in India, while Big Tech giants GOOGL $313.31 ▲ 3.03%, AMZN, META $652.50 ▲ 2.00%, and MSFT $386.12 ▼ 2.54% are set to collectively invest an estimated $650 billion in AI infrastructure this year, according to Bridgewater. However, legendary investor Michael Burry warned on AI spending, while Bridgewater cautioned the AI boom is entering a 'more dangerous phase,' suggesting a growing divide in market sentiment regarding the sector's long-term sustainability. Notably, AAPL $266.24 ▲ 2.83% appears to be somewhat insulated from some of the 'Big Tech' AI-related pressures.

Amid the equity market's retreat, safe-haven asset Gold is on track for its longest winning streak in history, trading near all-time highs. This surge is attributed to central bank buying, dollar weakness, low real yields, and persistent geopolitical tensions.

In other corporate news, Domino's DPZ rallied after beating sales estimates, indicating resilience in the quick-service pizza category. Conversely, WBA widened job cuts amid ongoing store closures, and HOG, HTGC, and AVTR all hit 52-week lows. ORCL $139.08 ▼ 9.40% slid on 'Stargate project' concerns, and VF VFC was downgraded by JPM on a longer margin recovery outlook. Positive individual news included VIV exceeding earnings forecasts, LINC beating Q4 revenue, and RELY receiving a price target raise from Cantor Fitzgerald. Meanwhile, ITRI president sold $5.58 million in stock.

Tariffs & Pharma Drags Market; AMZN Crowns Retail King, AI Powers On

U.S. equities are retreating from the open, with the S&P 500 SPY $687.68 ▲ 0.80% down as renewed concerns over global tariffs weigh on risk appetite. Despite earlier clarity on some past trade duties, "tariff uncertainty" is pushing the broader market lower, overshadowing a flurry of corporate news.

The pharmaceutical sector is seeing significant volatility. NVO shares are plunging after its next-generation weight loss drug failed to match a rival product from LLY $1076.03 ▲ 5.09% in a key trial, intensifying the competitive landscape. Conversely, LLY $1076.03 ▲ 5.09% is advancing with a new, more convenient form of its Zepbound obesity drug. Biotech M&A remains active, with GILD $149.40 confirming its $7.8 billion acquisition of cancer therapy developer ACLX, sending ACLX shares soaring. However, not all trial news is good: GOSS stock has tumbled 80% on a trial miss, while MoonMLTX surged on positive data. Meanwhile, ARMP gained on an FDA designation and AXGN looks to earnings after an FDA milestone.

In retail, AMZN $206.03 ▲ 0.63% has officially surpassed WMT $123.69 ▲ 0.45% in annual revenue for the first time in 13 years, a milestone driven by AMZN $206.03 ▲ 0.63%'s robust logistics, cloud (AWS), and AI investments. This highlights the ongoing digital transformation in the sector. Bernstein SocGen cut W on margin concerns but reiterated an Outperform for TJX TJX $158.14 ▲ 1.07%.

The artificial intelligence narrative continues to build. Google spinout Aalyria secured a $1.3 billion valuation, reflecting investor interest in space-based communications. OpenAI is deepening its enterprise push with multi-year deals with consulting giants, helping clients integrate AI agents. MSFT $388.56 ▼ 1.93%'s Azure platform is also expanding its reach with new secure access solutions. In quantum computing, IQM Quantum Computers plans a U.S. listing with a $1.8 billion valuation, backed by tech giants including MSFT $388.56 ▼ 1.93%, GOOGL $315.95 ▲ 3.90%, IBM $242.02 ▼ 22.49%, and CSCO $79.25 ▲ 1.19%. Additionally, ASML ASML unveiled an EUV light source advance expected to boost chip production, and DELL saw its target cut on rising memory costs. Bitcoin exchange COIN saw some reassurance that institutional interest remains despite recent declines.

Other notable movers include EHAB surging on an acquisition deal and AMC AMC beating revenue estimates. STLA anticipates a U.S. sales turnaround with its new Jeep Cherokee. Conversely, IP is down on falling containerboard prices, and UBER $74.30 ▼ 11.67% is slightly lower after rolling out its "Autonomous Solutions" platform. Federal Reserve Governor Waller indicated the upcoming jobs report, not tariff rulings, would be key for March interest rate decisions, shifting focus back to economic data. Several stocks hit 52-week lows, including TOST, PCTY, SS&C SSNC, and DGOC, reflecting broader market pressures in some segments.

Tariff Clouds Linger; Pharma Giant NVO Plunges; AI Mixed

Wall Street futures are signaling a cautious open this Monday, as renewed concerns over global tariffs continue to weigh on investor sentiment. This comes despite earlier clarity from a Supreme Court ruling, with market participants now grappling with reports of fresh protectionist measures and "pure tariff chaos" from European officials. The macro backdrop remains uncertain as the week begins.

In a significant pre-market shake-up, NVO shares are plunging after its next-generation weight loss drug reportedly failed to match the efficacy of a rival product from LLY $995.00 ▼ 2.82% in a critical trial. This development intensifies competition in the high-stakes obesity drug market, creating a major ripple effect for both pharmaceutical giants.

Elsewhere, individual company news provides a mixed bag. VRE is surging pre-market on news of a $3.4 billion sale agreement, while VRSK gains on a substantial $1.5 billion share buyback plan. Wells Fargo has upgraded GOOGL $313.88 ▲ 3.21% to "Overweight," citing its widening lead in AI capacity. The biotech sector also sees significant M&A action, with GILD $150.31 announcing a $7.8 billion buyout of cancer treatment partner ACLX, sending ACLX shares soaring. Additionally, MRK $122.37 ▲ 0.33% is planning a strategic spin-off of its cancer business to mitigate upcoming patent losses for its blockbuster drug Keytruda.

However, the broader tech sector faces headwinds beyond individual upgrades. Some analysts are suggesting the "Magnificent Seven" are becoming the "Lag 7," raising concerns about the concentration of market cap and potential drag on the overall S&P 500 SPY $688.60 ▲ 0.93%. On the downside, Deutsche Bank cut HRMY due to patent risk. In retail, AMZN $209.98 ▲ 2.55% has reportedly surpassed WMT $122.83 ▼ 0.25% in annual revenue for the first time in 13 years, driven by its robust cloud and logistics investments, highlighting intense competition at the top. As the opening bell approaches, traders will be looking for clearer direction amidst these divergent forces.

Trade Fears Weigh on Futures; Pharma Shifts, AI Shines

U.S. equity futures are edging lower this Monday morning, signaling a cautious start to the week as global trade uncertainty persists. Reports of continued U.S. tariff rhetoric are overshadowing earlier clarity from a Supreme Court ruling, contributing to a general "Risk-Off" tone across broader markets, with commodities like oil also pulling back amid U.S.-Iran talks.

On the corporate front, a major shake-up is hitting the pharmaceutical sector. NVO is seeing its shares plunge pre-market, wiping out significant gains after its next-generation weight loss drug reportedly failed to match the efficacy of a rival product in a critical trial. Conversely, the biotech space is seeing M&A action, with GILD $150.31 announcing a substantial $7.8 billion buyout of cancer treatment partner ACLX, sending ACLX shares soaring. Elsewhere, MRK $122.37 ▲ 0.33% is planning to spin off a separate cancer business to mitigate upcoming patent losses for its blockbuster drug Keytruda, a strategic move receiving a somewhat positive sentiment.

Artificial intelligence continues to drive analyst upgrades. Wells Fargo has boosted GOOGL $313.88 ▲ 3.21% to "Overweight," citing its widening lead in AI capacity, while Citi has named two unnamed chip stocks as new "Top Picks." DA Davidson also reiterated a "Buy" rating on NVDA $189.75 ▲ 1.73% ahead of its upcoming earnings, reinforcing the AI narrative. However, not all news is positive: Goldman Sachs has cut mining giant RIO to "Neutral" after its significant rally, and NCLH received a reiterated negative rating from Wells Fargo due to execution concerns. Utility provider PPL PPL also announced a $1 billion equity units offering, which could be dilutive to existing shareholders.

Futures Edge Lower on Tariff Worries; Pharma Shake-Up, AI in Focus

Wall Street futures are trading cautiously lower this Monday morning, signaling a hesitant start to the week as concerns over global trade policy persist. Despite earlier clarity from a Supreme Court ruling easing some prior tariffs, renewed calls for protectionist measures and "pure tariff chaos" from European officials are weighing on investor sentiment.

In individual stock news, a major shockwave is hitting the pharmaceutical sector. NVO shares are plunging pre-market, down significantly after its next-generation weight loss drug reportedly failed to match the efficacy of a rival product from LLY $995.00 ▼ 2.82% in a crucial trial, intensifying competition in the lucrative obesity drug market.

The artificial intelligence narrative continues to evolve. NVDA $189.75 ▲ 1.73% plans a return to the PC market with new AI laptop chips, aiming to expand its reach beyond data centers. Elsewhere, MSFT $397.31 ▲ 0.28% saw its Azure platform gain certification for Reltio Data Cloud, bolstering its enterprise AI capabilities. VRT is also highlighted as a top holding among major funds, benefiting from AI infrastructure demand. However, the AI boom presents mixed signals for others; while Samsung reportedly leverages the AI chip shortage, it could pressure AAPL $264.13 ▲ 2.02%. Broader software companies, though, are facing warnings of higher borrowing costs and tougher scrutiny as AI disrupts business models.

Other corporate updates include Domino’s DPZ, which is seeing shares rise after beating U.S. sales estimates, attracting budget-conscious customers with its deals. Pharmaceutical company LUPIN also received a positive nod with European Commission approval for its biosimilar Ranibizumab. On the macro front, global copper inventories have surged to multi-year highs, a potential indicator of oversupply or slowing industrial demand. Investors will also be watching HD $390.30 ▲ 3.31% and Lowe's LOW $279.93 ▲ 0.54%, set to report earnings later this week.

Pre-Market: Pharma Shockwave as NVO Falters; Trade Fears Mount

The pre-market session is being dominated by a significant pharmaceutical setback, as NVO shares are plunging by as much as 10% after its next-generation weight loss drug failed to match the efficacy of a rival product from LLY $995.00 ▼ 2.82% in a critical trial. This development creates a major competitive ripple in the high-stakes obesity drug market.

Broader market sentiment remains cautious amid persistent global trade jitters. European officials are vocally hitting back at what they term "pure tariff chaos" from the U.S., warning that existing trade deals are now at risk and reinforcing concerns that have seen European indices retreat. This trade uncertainty is also reflected in commodity markets, with gold and silver prices surging on geopolitical tensions. Adding to the negative corporate news from Europe, JMAT shares continue to sink after HON $235.90 ▼ 2.15% trimmed its acquisition deal for JMAT's Catalyst Technologies unit by a reported $500 million, with HON citing postponed 'green deals' as a factor.

Despite the headwinds, several companies are finding positive traction. Wells Fargo has upgraded GOOGL $313.88 ▲ 3.21%, citing its robust compute capacity expansion. The e-commerce "Buy Now, Pay Later" sector is also highlighted as a $40.88 billion market by 2030, with key players like AMZN $209.98 ▲ 2.55%, ALIZ, and BFH poised for growth. Other positive news includes LDA jumping 8% on strong combined ratio results, HAV announcing a share buyback, and JPJPM $306.79 ▼ 0.48% maintaining a bullish outlook on international stocks, citing favorable macro conditions.

Europe Slides on Trade Jitters; Select Stocks Rise

European markets are extending their retreat in early pre-market trading, with both Germany's DAX and the UK's FTSE 100 seeing declines. The cautious sentiment stems from persistent worries over heightened U.S. trade uncertainty and broader geopolitical tensions, including reports of EU aid to Ukraine being blocked. This extends the downbeat tone from earlier in the morning.

Despite the macro headwinds, several individual stocks are making headlines with positive catalysts. JD JD shares are surging following news of a significant £200 million buyback program, while EXOS reported robust Q4 2025 growth and strong guidance. Italian utility ENEL is also jumping after unveiling a substantial €53 billion investment plan focused on renewables. Adding to the positive corporate news, Wells Fargo upgraded GOOGL $313.88 ▲ 3.21%, citing its compute capacity expansion.

On the downside, JMAT shares are sinking 15% after Honeywell (HON) reportedly trimmed its acquisition deal for JMAT's Catalyst Technologies unit, suggesting a less favorable outcome for the former. Italian football club Società SSL also dropped after dismissing Qatari takeover interest, and AD was downgraded by KBC Securities. Commodity markets are reflecting the geopolitical worries, with gold and silver prices surging.

The mixed bag of global trade jitters and specific corporate action points to a potentially choppy start for U.S. markets, with investors likely remaining in a 'Wait-and-See' mode.

Europe Slides on Trade Jitters; Individual Stocks Buoyed

European equities are retreating in early trading, signaling renewed caution as global trade uncertainty appears to be weighing on risk appetite. This comes despite earlier clarity regarding the cessation of some previous U.S. tariffs, suggesting the overarching macro picture remains complex.

Against this backdrop, several companies are seeing positive pre-market action based on analyst upgrades and solid performance reports. Baird has upgraded HSIC, citing optimism for a recovery in the dental market. ETHO is also garnering attention, with both Barclays and Citizens initiating coverage at "overweight" and "outperform" ratings, respectively. Automotive supplier HLE reported higher 2025 profit and offered a positive 2026 outlook, potentially buoying its shares. Additionally, JYSK's continued share buyback program could lend support.

The divergent corporate news, set against a backdrop of renewed European trade concerns, keeps the broader pre-market sentiment firmly in a 'Wait-and-See' posture as investors await the U.S. open.

Pre-Market Buzz: RDDT Bullish Call, PNL Cuts Dividend Amid Acquisition News

As markets anticipate Monday's open, the pre-market landscape is shaped by a mix of corporate news, layered on top of earlier clarity regarding U.S. tariff policy. Following the Supreme Court's ruling, which will cease collection of prior Trump tariffs, the broader trade narrative appears somewhat stabilized, though investors are now sifting through individual company developments.

Investment chatter is buzzing around RDDT, with a deep-dive analysis pegging a strong 'Buy' signal at a $150 valuation, potentially drawing attention to related AI plays. Conversely, PostNL PNL faces significant headwinds, having announced a a drastic 43% cut to its FY25 dividend and warning of continued cash burn into 2026, signaling financial pressure. In strategic corporate action, HON $235.90 ▼ 2.15% has finalized its acquisition of Johnson Matthey's JMAT Catalyst Technologies unit for £1.3 billion, a move that could be seen as positive for both companies as HON expands its portfolio and JMAT streamlines operations. Overall, the divergent corporate news keeps pre-market sentiment in a 'Wait-and-See' mode.

Tariff Relief Emerges as SC Ruling Takes Effect; Earnings Mixed

The trading week is set to open with markets navigating conflicting signals surrounding trade policy. While earlier reports highlighted fresh global tariff threats from former President Trump, analysts suggest markets are largely unfazed by these latest salvos. Crucially, U.S. customs has confirmed it will cease collecting prior Trump tariffs from February 24th, directly implementing a recent Supreme Court ruling. This concrete development has provided a notable boost, with Chinese export stocks rising and JPMorgan upgrading companies like Thai Union (TU.BK) and Sun Hung Kai Properties (0016.HK), citing improved tariff clarity and valuation shifts.

Despite this tariff clarity, the broader landscape remains mixed. Australia's LLC plunged to a near four-decade low after swinging to a first-half loss. Swiss firm Belimo (BELN.SW), despite reporting record FY25 sales, warned of a potential Q1 hit from tariffs. Geopolitical tensions also persist in Europe, with Hungary reportedly blocking EU Russia sanctions over a pipeline dispute.

On a more positive note, GDI GDI saw its Funds From Operations (FFO) surge 29% in H1 2026, driven by strong leasing momentum. Additionally, analysts are highlighting a strong setup for KLRS, and broader profit expectations for 2026 have been significantly revised upwards. Overall, while some corporate optimism persists, the mixed bag of trade rhetoric, specific company woes, and geopolitical friction points to a 'Wait-and-See' approach ahead of the Monday open.

Global Tariff Threat Widens to Currency Markets

The market is entering Monday with a reinforced sense of caution as the implications of new global tariff threats continue to unfold. Reports indicating former President Trump's order for fresh 10% tariffs have begun to reverberate beyond initial risk assets like BTC, which previously saw a tumble. Overnight, the uncertainty around U.S. tariff policy contributed to Asian currencies ticking higher and the U.S. dollar slipping, signaling broader market apprehension.

Adding to the headwinds, revisions to the January Jobs Report have confirmed a weaker labor market picture, further dampening economic sentiment. This combination of potential trade friction and softer employment data is likely to set a defensive tone for the upcoming trading week, keeping investors in a 'Wait-and-See' mode ahead of the opening bell.

Global Tariffs, Weak Jobs Data Set Cautious Tone

The trading week is poised to begin under a cloud of renewed trade uncertainty and fresh economic concerns. Following reports that former President Trump has ordered new 10% global tariffs, China's Commerce Ministry has confirmed it is evaluating the ruling, signaling a potential escalation of trade tensions that had just seen a brief respite. This development directly challenges the 'Risk-On' sentiment that closed out last week after the Supreme Court's prior tariff decision. Adding to the cautious outlook, revisions to the January Jobs Report revealed a weaker labor market than initially estimated, suggesting a potential slowdown in economic activity.

This confluence of factors has already impacted risk assets overnight, with BTC tumbling below $65,000 amid 'US tariff jitters' and reported whale selling. These developments are likely to overshadow some of the prior week's positive momentum from significant investments in the AI sector, leaving investors in a 'Wait-and-See' mode ahead of the Monday open.